Summary by Moomoo AI
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, filed its unaudited condensed interim consolidated financial statements for the three months ended January 31, 2024, with the Canadian Securities Administration and relevant provincial commissions on March 18, 2024. The report, prepared in accordance with International Financial Reporting Standards, indicates a net loss of $1,367,800 for the period, a decrease from the previous year's loss of $1,899,469. Research costs decreased to $227,478 from $587,630, while general and administrative expenses also saw a reduction. The company reported significant developments, including a completed Type A meeting with the U.S. FDA regarding its clinical trial for the proprietary MEAI-based CMND-100 compound for Alcohol Use Disorder treatment. Clearmind also completed a registered direct and private placement for $2.4 million, and announced a...Show More